The prognostic value of AGR2 expression in solid tumours: a systematic review and meta-analysis

Shao-bo Tian1,2, Kai-xiong Tao1, Jia Hu1, Zhi-bo Liu1,2, Xue-liang Ding1, Ya-nan Chu1, Jin-yuan Cui1, Xiao-ming Shuai1, Jin-bo Gao1, Kai-lin Cai1, Ji-liang Wang1, Guo-bin Wang1, Lin Wang2,3 & Zheng Wang1,2

The prognostic value of anterior gradient-2 (AGR2) in tumours remains inconclusive. Here, we systematically reviewed the literature evidence and assessed the association between AGR2 expression and prognosis in solid tumours. The primary outcomes were overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS)/recurrence-free survival (RFS)/progression-free survival (PFS). All analyses were performed by STATA 12.0, with the hazard ratio (HR) or odds ratios (OR), and 95% confidence interval (CI) as the effect size estimate. A total of 20 studies containing 3285 cases were included. Pooled analyses revealed that AGR2 overexpression had an unfavourable impact on OS (HR 1.93, 95% CI 1.32–2.81) and time to tumour progression (TTP) (DFS/RFS/PFS) (HR 1.60 95% CI 1.06–2.40) in solid tumour patients. Subgroup analyses indicated that AGR2 overexpression in breast cancer patients was significantly associated with poor OS (HR 3.02, 95% CI 1.03–8.81) and TTP (HR 1.93, 95% CI 1.17–3.20). Excluding breast cancer, AGR2 overexpression was also found to have a significant correlation with poor OS in the remaining solid tumour patients (HR 1.51, 95% CI 1.04–2.19). Overall, AGR2 might be a potential biomarker to predict prognosis in solid tumour patients.

The human anterior gradient-2 (AGR2), a homologue of xenopus anterior gradient-2 (XAG-2) of Xenopus laevis1, is a member of the protein disulfide isomerase (PDI) gene family. AGR2 protein weighs 19 kDa containing a short N-terminal signal peptide and a C-terminal endoplasmic reticulum retention sequence (KTEL)2. AGR2, physiologically localized in endoplasmic reticulum (ER), has emerged as a critical modulator of ER homeostasis3,4. A growing body of evidence supports a functional role of AGR2 in a variety of cellular functions, such as cell migration, differentiation and proliferation3.

Since AGR2 was found to be as a pro-oncogenic protein that attenuates p53 activity in 20046, AGR2's molecular role and its clinical relevance have been increasingly investigated in cancers, including breast7,8, lung9, ovarian10, prostate11, pancreatic cancer12, and colorectal carcinomas13. Although high AGR2 expression in breast and lung cancer was reportedly correlated with poor clinical prognosis14,15, some studies suggested the otherwise, thus resulting in a controversy16. Moreover, in other types of cancer, such as prostate cancer, ovarian cancer and colorectal cancer, the prognostic value of AGR2 remains largely inconclusive17–19. Aiming to explore the prognostic value of AGR2 in these solid tumours, we conducted this comprehensive meta-analysis.

Results

Description of the selected studies. A total of 824 studies were initially identified using our search strategy from PubMed, Embase, and Web of Science database (Fig. 1). 791 studies were discarded because of either

1Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 2Research Centre for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 3Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Shao-bo Tian and Kai-xiong Tao contributed equally to this work. Correspondence and requests for materials should be addressed to G.-b.W. (email: wgb@hust.edu.cn) or L.W. (email: lin_wang@hust.edu.cn) or Z.W. (email: zhengwang@hust.edu.cn)
duplication (479) or irrelevance (312). Out of 32 studies eligible for further assessment, 12 studies were excluded with 10 of them lacking prognosis data and the rest of two studies having insufficient data for estimating HR with 95% CI. Therefore, 20 studies (19 in English and 1 in Chinese) with a total number of 3285 patients were used for analysing the relationship between AGR2 expression and solid tumour patients' prognosis. These 20 included studies were of high methodological quality with their Newcastle-Ottawa Scale (NOS) scores ranging from 6 to 9.

The main features of the 20 eligible studies were extracted and summarized in Table 1. These studies were conducted in nine countries with 13 studies originated from Europe (5 from Germany; 4 from UK; 3 from Czech Republic; 1 from Spain), 5 from Asia (2 from China; 2 from Japan; 1 from Singapore), 1 from USA, and 1 from Australia. These studies were published between 2005 and 2016. The median follow-up time of the 14 studies with definite follow-up duration was 53 months (ranging from 23 to 192). As for cancer types, breast cancer was the most frequent cancer type (n = 9), followed by lung cancer (n = 4), prostate cancer (n = 2), ovarian cancer (n = 2), colorectal cancer (n = 2), and gastric cancer (n = 1). Given that DFS /RFS /PFS are similar outcome endpoints, we thus used the time to tumour progression (TTP) to represent these three survival parameters in our meta-analysis. TTP referred to the length of time from the date of diagnosis or the treatment starting date to the date when the disease condition started to progress again or metastasis was detected. In these studies, quantitative reverse transcription polymerase chain reaction (qRT-PCR) (n = 2) or immunohistochemistry (IHC) staining (n = 16) was used to detect AGR2 expression in tumour tissue, while ELISA (n = 1) or qRT-PCR (n = 1) was employed to measure AGR2 expression in serum samples. The mean expression level (Table 1) was the most frequently used cut-off value for AGR2 positive expression across these studies.

**Impact of high AGR2 expression on cancer prognosis.** Concerning the survival outcomes in patients with solid malignancies, 13 studies evaluated the relationship between AGR2 expression and OS, while 8 studies analysed the association of AGR2 expression with TTP and two studies with DSS. OS was indicated by the percentage of patients who remained alive at a given time point. DSS was indicated using the percentage of subjects who survived a particular disease for a defined period of time. The estimated pooled HRs showed that compared with AGR2 low/ negative expression, AGR2 overexpression/ positivity was highly related to poor OS (HR 1.93, 95% CI 1.32–2.81) and poor TTP (HR 1.60, 95% CI 1.06–2.40) of solid tumour patients. However, no association was found between AGR2 overexpression and DSS (HR 0.36, 95% CI 0.06–2.14). These pooled analyses were conducted using the random effects model, in which significant heterogeneity of the included studies on OS (I² = 83.2%, P = 0.000), TTP (I² = 65.2%, P = 0.003) and DSS (I² = 77.6%, P = 0.035) was observed, indicating that the choice of this model was appropriate (Table 2).

**Subgroup analysis.** To identify the contributing factors underlying heterogeneity, subgroup analyses by cancer types and study location were conducted (Table 2). If only one study provided relevant data on the correlation of AGR2 overexpression with outcome endpoints, the subgroup analysis was not performed. The subgroup analysis by study location indicated that 13 studies reporting OS were stratified into Europe (n = 9), Asia (n = 3), and USA (n = 1); 9 studies focused on TTP were stratified into Europe (n = 6), Asia (n = 2), and Oceania (n = 1). According to the different study locations, subgroup analyses did not reveal any significant correlation between AGR2 overexpression and the OS of solid tumour patients (in Europe: HR 1.96, 95% CI 0.99–3.85; in Asia: HR 1.91 95% CI 0.95–3.84). Furthermore, the heterogeneity could not be reduced by location stratification either (in Europe: I² = 84.8%, P = 0.000; in Asia: I² = 86.9%, P = 0.000). However, we observed a significant
Table 1. Characteristic of the included studies. Abbreviations: NA: not available; IHC: Immunohistochemistry; QRT-PCR: Quantitative Real Time Polymerase Chain Reaction; NOS: Newcastle-Ottawa Scale; OS: overall survival; DSS: disease specific survival; DFS: disease free survival; RFS: recurrence free surviv.

| Cancer type        | Study                  | Country     | Case | Age median | Test method | location    | Cut-off value                                                                 | Follow-up time (range) months | Outcome endpoints | NOS |
|--------------------|------------------------|-------------|------|------------|-------------|-------------|--------------------------------------------------------------------------------|-------------------------------|-------------------|-----|
| Prostate cancer    | Kristiansen et al. 17   | Germany     | 91   | 63         | IHC         | tumour      | Positive: weak & intermediate & strong positivity                     | 30.5 (2–84)                   | DFS              | 8   |
|                    |                        |             |      |            |             |             | Negative: complete absence of immunoreactivity                        |                               |                   |     |
| Breast cancer      | Fritzsche et al. 18     | Germany     | 155  | 59         | IHC         | tumour      | Positive: (score = 1–12)                                            | 75 (11–162)                   | OS, DFS          | 8   |
|                    |                        |             |      |            |             |             | Negative: (score = 0) (Range of 0–12)                                  |                               |                   |     |
| Breast cancer      | Innes et al. 11         | UK          | 225  | 64         | IHC         | tumour      | Positive: ≥ 1% carcinoma cells stained                               | 85 (90.1–212)                 | OS              | 8   |
|                    |                        |             |      |            |             |             | Negative: < 1% carcinoma cells stained                                |                               |                   |     |
| Lung cancer        | Fritzsche et al. 17     | Germany     | 77   | 62         | IHC         | tumour      | Positive: score H2                                                  | 23 (0–92)                     | DSS              | 8   |
|                    |                        |             |      |            |             |             | Negative: score 0 (Range of 0–2)                                     |                               |                   |     |
| Prostate cancer    | Zhang et al. 20         | UK          | 65   | 73         | IHC         | tumour      | Positive: (2–16)                                                 | NA                            | OS              | 7   |
|                    |                        |             |      |            |             |             | Negative: (1) (Range of 1–16)                                       |                               |                   |     |
| Breast cancer      | Wu et al. 21           | China       | 72   | 50         | IHC         | tumour      | Positive: stained in the cytoplasm, yellow or brown particles      | 60 (8–64)                     | OS              | 8   |
|                    |                        |             |      |            |             |             | Negative: complete absence                                           |                               |                   |     |
| Breast cancer      | Baraclough et al. 18    | UK          | 315  | 57         | IHC         | tumour      | Positive: ≥ 1% carcinoma cells stained                               | 192 (168–240)                 | OS              | 8   |
|                    |                        |             |      |            |             |             | Negative: < 1% carcinoma cells stained                               |                               |                   |     |
| Breast cancer      | Hrstka et al. 19        | Czech Republic | 78  | NA         | QRT-PCR     | tumour      | High: > the mean expression levels                                  | 48                            | DFS              | 7   |
|                    |                        |             |      |            |             |             | Low: ≤ the mean expression levels                                    |                               |                   |     |
| Lung cancer        | Chung et al. 20         | Japan       | 111  | 68         | ELISA       | serum       | Positive: > 2.6 ng/ml                                               | 36 (4–77)                     | OS, DFS          | 8   |
|                    |                        |             |      |            |             |             | Negative: ≤ 2.6 ng/ml                                               |                               |                   |     |
| Lung cancer        | Chung et al. 20         | Japan       | 212  | 67         | IHC         | tumour      | Positive: > 50% carcinoma cells stained                              | 24 (3–61)                     | DSS              | 8   |
|                    |                        |             |      |            |             |             | Negative: < 1% carcinoma cells stained                               |                               |                   |     |
| Breast cancer      | Radlind et al. 16       | UK          | 137  | 60.3       | IHC         | tumour      | Positive: ≥ 1% carcinoma cells stained                               | 192 (168–240)                 | OS              | 8   |
|                    |                        |             |      |            |             |             | Negative: < 1% carcinoma cells stained                               |                               |                   |     |
| Colorectal Cancer  | Valladasares-Ayeres et al. 17 | Spain       | 54   | 62.7       | QRT-PCR     | serum       | High: > the mean expression levels                                  | 58 (17–84)                    | OS, PFS          | 8   |
|                    |                        |             |      |            |             |             | Low: ≤ the mean expression levels                                    |                               |                   |     |
| Ovarian cancer     | Darb-Esfahani et al. 19 | Germany     | 124  | NA         | IHC         | tumour      | High: > 50% carcinoma cells stained                                  | 45 (2.5–162.3)                | OS, PFS          | 8   |
|                    |                        |             |      |            |             |             | Low: ≤ 50% carcinoma cells stained                                   |                               |                   |     |
| Ovarian cancer     | Armes et al. 16         | Australia   | 59   | NA         | IHC         | tumour      | Positive: > 50% carcinoma cells stained                              | NA                            | DFS              | 7   |
|                    |                        |             |      |            |             |             | Negative: ≤ 50% carcinoma cells stained                             |                               |                   |     |
| Breast Cancer      | Hrstka et al. 19        | Czech Republic | 61  | 79         | QRT-PCR     | tumour      | High: > the mean expression levels                                  | NA                            | OS, PFS          | 8   |
|                    |                        |             |      |            |             |             | Low: ≤ the mean expression levels                                    |                               |                   |     |
| Colorectal Cancer  | Rienen et al. 19        | Germany     | 432  | 72         | IHC         | tumour      | High: score 2 or 3                                                | 42 (1–153)                    | OS              | 9   |
|                    |                        |             |      |            |             |             | Low: score 0 or 1 (Range of 0–3)                                    |                               |                   |     |
| Lung cancer        | Alavi et al. 18         | USA         | 155  | NA         | IHC         | tumour      | High: > the mean expression levels                                  | NA                            | OS              | 7   |
|                    |                        |             |      |            |             |             | Low: ≤ the mean expression levels                                    |                               |                   |     |
| Breast Cancer      | Hrstka et al. 19        | Czech Republic | 234 | NA         | IHC         | tumour      | High: > the mean expression levels                                  | NA                            | RFS             | 7   |
|                    |                        |             |      |            |             |             | Low: ≤ the mean expression levels                                    |                               |                   |     |
| Breast Cancer      | Lacambra et al. 13      | Singapore   | 400  | 53.9       | IHC         | tumour      | Positive: ≥ 5% of cells with strong to moderate cytoplasmic staining| 61.3 (3–210)                  | DFS              | 8   |
|                    |                        |             |      |            |             |             | Negative: < 5% of cells with strong to moderate cytoplasmic staining|                               |                   |     |
| Gastric cancer     | Zhang et al. 22         | China       | 228  | NA         | IHC         | tumour      | High: the product of the staining intensity and proportion of stained tumor cells scores ≥ 4 | 7 NA                         | OS              | 7   |
|                    |                        |             |      |            |             |             | Low: the product of the staining intensity and proportion of stained tumor cells scores < 3 |                               |                   |     |

Notably, in breast cancer patients, AGR2 overexpression could predict poor outcomes (OS: HR 3.02, 95% CI 1.53–8.81; TTP: HR 1.93, 95% CI 1.32–2.81), but not TTP (HR 1.60 95% CI 1.06–2.40) (Fig. 3). These results demonstrate that AGR2 overexpression can be the prognostic factor for the OS of solid tumour patients. Begg’s test and Egger’s test as well as funnel plots revealed no obvious association between AGR2 overexpression and poor TTP (HR 1.88, 95% CI 1.20–2.94) with no obvious heterogeneity ($I^2 = 45.4\%, P = 0.103$) in the studies from Europe, suggesting that the study location might partially account for the heterogeneity among the studies on TTP.
publication bias concerning OS and TTP in the subgroup analysis for breast cancer patients (Fig. 4c and d). However, high heterogeneity among breast cancer studies was identified for OS ($I^2 = 81.2\%$, $P = 0.000$), but not for TTP ($I^2 = 38.7\%$, $P = 0.180$). Thus, we set to address the heterogeneity for OS in breast cancer patients by further performing subgroup analyses on study location, follow-up time, estrogen receptor (ER) status, and sample size. The subgroup analysis showed an improved HR in the studies with large sample size ($\geq 200$, HR 4.88, 95% CI 1.60–14.85) and long follow-up time ($\geq 80$ months, HR 6.14, 95% CI 2.53–14.92). Moreover, the heterogeneity across the studies with large sample size ($I^2 = 57.3\%$, $P = 0.216$) and long follow-up time ($I^2 = 50.2\%$, $P = 0.134$) were found to be effectively reduced. The subgroup analysis on ER status also confirmed the unfavourable impact of AGR2 overexpression on the OS of ER positive breast cancer patients (HR 2.58, 95% CI 1.06–6.26). In terms of study location, no significant association between AGR2 overexpression and poor OS was identified in breast cancer studies from Europe (HR 2.48, 95% CI 0.79–7.81) (Table 3).

Correlation of AGR2 expression with clinicopathological features of breast cancer. To fully elucidate AGR2’s clinical relevance in breast cancer, we assessed the relationship between AGR2 overexpression and clinicopathological features of breast cancer patients. As illustrated in Table 4, AGR2 overexpression correlated positively with ER status (positive vs negative: OR 4.08, 95% CI 2.16–7.69), PgR status (positive vs negative: OR 2.87, 95% CI 2.17–3.80), and negatively with histological grade (III vs I-II: OR 0.42, 95% CI 0.19–0.93). However, no obvious correlation was found with tumour size ($\leq 5$ cm vs $> 5$ cm: OR 1.35, 95% CI 0.83–2.18), tumour TNM stages (T3 & T4 vs T1 & T2: OR 1.21, 95% CI 0.76–1.92), lymphovascular invasion (LVI) (positive vs negative: OR 1.11, 95% CI 0.84–1.46), and HER-2 status (positive vs negative OR 2.51, 95% CI 0.84–7.51). Additionally, the heterogeneity was not obvious in the meta-analysis of tumour size, tumour TNM stages, lymphovascular invasion and PgR status ($I^2 0–25.8\%)$.

Sensitivity and publication bias. The sensitivity analyses were performed by omitting one study at a time to gauge the robustness of our results. We found that the pooled HRs was not significantly altered by excluding any single study, demonstrating that the results of this meta-analysis are statistically robust (Fig. 5). Furthermore, the publication bias in the included studies was assessed by combining the Begg’s funnel plot and Egger’s test. The results indicated no evidence for publication bias, as all $P$ value for Begg’s test and Egger’s test were $> 0.05$ (Fig. 4).

Discussion

AGR2 mainly expressed in epithelial cells in human\(^{34}\). As a member of PDIs, AGR2 plays a pivotal role in maintaining endoplasmic reticulum homeostasis through regulating the unfolded protein response signalling (UPR)\(^{35}\). In addition, AGR2 has been implicated in a range of cell biological processes, in particular cellular transformation, cell migration and adhesion\(^{36}\). Moreover, AGR2 reportedly acts as a pro-oncogenic protein overexpressed in various cancers and involved in adenocarcinoma growth, cell metastasis\(^{7,38}\) and drug resistance\(^{41}\). Paradoxically, many studies found that elevated AGR2 levels did not predict the poor outcomes of solid tumour patients\(^6,15\). Thus, the prognostic value of AGR2 in tumours remains elusive and needs to be clarified.

In this article, we systematically evaluated AGR2 expression and the survival data of 3285 solid tumour patients from 20 different studies. Overall, our results demonstrated that AGR2 overexpression could predict poor OS (HR1.93, 95% CI 1.32–2.81) and poor TTP (HR1.60, 95% CI 1.06–2.40) of all solid tumour patients. These HR estimates were robust with no publication bias. However, high heterogeneity was observed across the studies included for this meta-analysis. The sensitivity analysis in this meta-analysis did not help to elucidate the source of heterogeneity. Therefore, we conducted subgroup analysis by study location and cancer types to address the source of heterogeneity. In subgroup analysis for breast cancer, both HR estimates for OS and TTP (OS: HR 3.02, 95% CI 1.57–5.83; TTP: HR 1.93, 95% CI 1.17–3.20) further indicates that AGR2 overexpression is predictive of poor prognosis in breast cancer patients. Meanwhile, the heterogeneity test showed no obvious
### Table 2. Hazard ratio for the association between AGR2 overexpression and solid tumours prognosis. Abbreviations: No.: number; HR: hazard ratio; CI: confidence interval; OS: overall survival; DSS: disease specific survival; TTP: time to tumor progression.

heterogeneity for TTP ($I^2 = 38.7\%$, $P = 0.180$), but it was still significant for OS ($I^2 = 83.2\%$, $P = 0.000$). Further subgroup analysis was then performed and the results suggest that heterogeneity across the studies with sample size $\geq 200$ ($I^2 = 57.3\%$, $P = 0.216$) or with follow-up time $\geq 80$ months ($I^2 = 50.2\%$, $P = 0.134$) can be effectively reduced, and the correlation of AGR2 overexpression with poor OS become significantly evident. Of note, subgroup analyses for the solid tumours group with breast cancer excluded showed that AGR2 overexpression was significantly associated with poor OS, but not with TTP. Thus, AGR2 might serve as a reliable prognostic marker for the OS of pooled patients with solid tumours.

We also analysed the relationship between AGR2 and clinicopathological features of breast cancer. Consistent with the previous study showing that AGR2 expression can be induced by estrogen in ERα expressing breast cancer cell lines, the upregulation of AGR2 was found significantly correlated with positive ER and PgR status as well as low histological grade. As previously reported that AGR2 expression promoted cell lineage differentiation in murine stomach, the co-expression of AGR2 and ER or PgR, and the association with the low histological grade indicated that AGR2 might be a marker of differentiation in breast cancer. However, in breast cancer patients, AGR2's high expression was predictive of poor outcomes. Further functional studies are needed to clarify AGR2's role in breast cancer.

Unlike its prognostic value in breast cancer, clinical effects of AGR2 expression on other tumour types remained inconclusive due to the existence of conflicting results. Alavi et al. and Fritzschke et al. conducted cohort studies to explore the correlation of AGR2 expression status with the prognosis of lung cancer patients.
AGR2 overexpression was found to contribute to the poor OS\(^1\). However, Fritzsche et al. found that AGR2 overexpression did not show any prognostic value in non-small-cell lung cancer (NSCLC)\(^2\). Interestingly, the other two studies focused on colorectal cancer and prostate cancer conducted by the same group (Fritzsche et al.) showed that in colorectal cancer AGR2's up-regulation was strongly associated with improved OS compared with the control, while no prognostic value of AGR2 could be detected in prostate cancer\(^1,2,19\). Of note, in contrast to other selected studies, Fritzsche et al. reported a rather opposite observation that AGR2 overexpression predicted longer overall survival time of breast cancer patients\(^20\). We speculate that these discrepancies might be partially caused by differences in experimental protocols, antibody concentrations, and criteria for high AGR2 expression used in different research groups. Since further analyses could not be performed due to the insufficient number of existing studies, current data led us to a speculation that AGR2 might truly function as a tumour suppressor in some tumour types\(^19\), which however awaited future experimental verifications, especially in lung cancer, prostate cancer, ovarian cancer, gastric cancer, and colorectal cancer.

Alternatively, the different impact of AGR2 expression on solid tumours might be due to an apparently distinct regulation in certain cancer types. AGR2 is the human orthologue of the Xenopus Anterior Gradient-2 (XAG-2) protein\(^1\). In the Xenopus embryo, XAG-2 plays a key role in patterning the cement gland, a mucus-secreting tissue\(^1\). Similarly, AGR2 is predominiately expressed in normal human colon, rectum, stomach, breast, and prostate\(^19\), which are the organs capable of secreting a variety of small molecules. Given that AGR2 was originally found in breast cancer specimen\(^1\), it is not surprising that almost half of the selected studies in this meta-analysis were breast cancer related. In normal mouse mammary glands, AGR2 is required for epithelial cell proliferation and lobuloalveolar development\(^19\). In breast cancer, AGR2 is co-expressed with estrogen receptor (ER) that directly regulates AGR2 expression\(^19\), and is significantly correlated with HER2 positive breast cancer\(^41\). Consistent with the previous studies, our study showed the co-expression of AGR2 and ER or PgR, and AGR2's association with the low histological grade might indicate that AGR2 is a molecular marker of differentiation. This is also supported by the fact that AGR2 expression promoted cell lineage differentiation in murine stomach\(^40\). Intriguingly, it seems paradoxical to the prognosis of breast cancer patients for whom AGR2's high expression predicted poor outcomes. A possible explanation would be that AGR2 overexpression might increase breast cancer cells' proliferative and invasive capacity. AGR2 overexpressed tumour cells was showed to have strong propensity for disseminating to lung\(^19\). Thus, we speculate that the mechanism for AGR2 overexpression predicting breast cancer's poor prognosis could be: AGR2 expression was induced in an ER- or HER-dependent manner at the early stage of tumorigenesis, which led to treatment resistance and metastasis.

Some limitations of our study include: first, the standards for defining AGR2 positivity across the studies vary due to different experimental methods used for assessing AGR2 expression, which might lead to inter-study heterogeneity. Second, the sample size and the number of studies from certain cancer types, such as lung cancer, prostate cancer, ovarian cancer, gastric cancer and colorectal cancer, appear to be quantitatively insufficient. Third, as a secreted protein, the significant elevation of AGR2 in pancreatic juice from pancreatic cancer patients or in urine from prostate cancer patients suggests that AGR2 may also function extracellularly during the development of cancer\(^1,19\). In addition, both studies by Kyukwang Chung et al. and Valladares-Ayerbes et al. reported that the presence of detectable AGR2 in serum was significantly associated with the poor OS or DFS\(^23,24\). However, we could not perform a further analysis for the prognostic value of secreted AGR2, because only 2 studies observed serum AGR2 among the included studies. Although the mechanisms and the rate of AGR2 secretion from cytoplasm of tumour cells into the blood serum in different cancers might vary considerably\(^26\), we speculated that

| Stratified analysis | NO. of study | References | Cases | Pooled HR (95% CI) | P value | Heterogeneity | I\(^2\) (%) | p value |
|--------------------|--------------|------------|-------|--------------------|---------|---------------|-----------|---------|
| Total              | 6            | Fritzsche et al.\(^2\); Innes et al.\(^2\); Wu et al.\(^2\); Barraclough et al.\(^2\); Rudland et al.\(^2\); Hrstka et al.\(^2\) | 995    | 3.02 (1.03–8.81)    | 0.044   | 81.2          | 0.000     |         |
| ER status          |              |            |       |                    |         |               |           |         |
| Positive           | 3            | Innes et al.\(^2\); Wu et al.\(^2\); Hrstka et al.\(^2\) | 388    | 2.58 (1.06–6.26)    | 0.036   | 60.6          | 0.079     |         |
| Negative           | 3            | Fritzsche et al.\(^2\); Barraclough et al.\(^2\); Rudland et al.\(^2\) | 607    | 2.26 (0.18–28.56)   | 0.530   | 88.5          | 0.000     |         |
| Study location     |              |            |       |                    |         |               |           |         |
| Europe             | 5            | Fritzsche et al.\(^2\); Innes et al.\(^2\); Barraclough et al.\(^2\); Rudland et al.\(^2\); Hrstka et al.\(^2\) | 923    | 2.48 (0.79–7.81)    | 0.122   | 83.5          | 0.000     |         |
| Asia               | 1            | Wu et al.\(^2\) | 72     | 12.42 (1.53–100.84)| 0.018   | —             | —         |         |
| Sample size        |              |            |       |                    |         |               |           |         |
| ≥ 200              | 2            | Innes et al.\(^2\); Barraclough et al.\(^2\) | 570    | 4.88 (1.60–14.85)   | 0.005   | 57.3          | 0.126     |         |
| < 200              | 4            | Fritzsche et al.\(^2\); Wu et al.\(^2\); Hrstka et al.\(^2\); Rudland et al.\(^2\) | 425    | 2.08 (0.35–12.32)   | 0.421   | 85.4          | 0.000     |         |
| Follow-up (months) |              |            |       |                    |         |               |           |         |
| ≥ 80               | 3            | Innes et al.\(^2\); Rudland et al.\(^2\); Barraclough et al.\(^2\) | 707    | 6.14 (2.53–14.92)   | 0.000   | 50.2          | 0.134     |         |
| < 80               | 3            | Fritzsche et al.\(^2\); Wu et al.\(^2\); Hrstka et al.\(^2\) | 288    | 1.10 (0.114–10.65)  | 0.935   | 82.8          | 0.003     |         |

Table 3. Subgroup analyses of the association between AGR2 overexpression and OS for breast cancer patients. Abbreviations: No.: number; HR: hazard ratio; CI: confidence interval; OS: overall survival. ER: estrogen receptor.

---

1. Fritzsche et al.
2. Innes et al.
3. Wu et al.
4. Barraclough et al.
5. Rudland et al.
6. Hrstka et al.
7. Kyukwang Chung et al.
8. Valladares-Ayerbes et al.
9. Wu et al.
10. Rudland et al.
11. Barraclough et al.
12. Hrstka et al.
13. Innes et al.
14. Barraclough et al.
15. Wu et al.
16. Rudland et al.
17. Innes et al.
18. Wu et al.
19. Barraclough et al.
20. Hrstka et al.
21. Innes et al.
22. Wu et al.
23. Barraclough et al.
24. Rudland et al.
25. Hrstka et al.
26. Innes et al.
27. Wu et al.
28. Rudland et al.
29. Hrstka et al.
30. Innes et al.
31. Wu et al.
32. Barraclough et al.
33. Rudland et al.
34. Hrstka et al.
35. Innes et al.
36. Wu et al.
37. Rudland et al.
38. Hrstka et al.
39. Innes et al.
40. Wu et al.
41. Rudland et al.
42. Hrstka et al.
43. Innes et al.
44. Wu et al.
45. Rudland et al.
46. Hrstka et al.
47. Innes et al.
48. Wu et al.
49. Rudland et al.
50. Hrstka et al.
assessing AGR2 expression in tumour tissue along with a blood test for AGR2 protein may potentially lead to a more accurate and comprehensive assessment of the prognostic role of AGR2 in tumours.

In summary, despite the above limitations, our meta-analysis demonstrates that high AGR2 expression can serve as a prognostic predictor of OS for solid tumour patients, especially for breast cancer patients. Furthermore, in breast cancer, high expression of AGR2 trends to correlate with ER positivity, PgR positivity and low

---

**Figure 3.** Meta-analysis of impact of AGR2 expression on prognosis of the solid tumours group (excluding the breast cancers). Forest plot of HRs for the correlation between AGR2 overexpression and OS (a) and TTP (b) in solid tumour patients.

---

**Figure 4.** Funnel plot of studies used in the analysis of AGR2 expression and the prognosis of patients with solid tumours. (a) OS for solid tumour patients. (b) TTP for solid tumour patients. (c) OS for breast cancer patients. (d) TTP for breast cancer patients.
histological grade. However, further analyses and more trials on other types of cancers are required to confirm our conclusions.

Methods

Search strategy and selection criteria. This present meta-analysis was executed in accordance with the Preferred Reporting Items for Systematics Reviews and Meta-Analyses guidelines. We performed a comprehensive literature search through the electronic databases PubMed, Embase, and Web of Science databases updated to January, 2017. We used the Medical Subject Heading (MeSH) terms and corresponding keywords to make the search strategy. The following combined search terms were used (“Anterior gradient 2” or HAG-2 or “Anterior gradient 2 homolog” or “Anterior gradient protein 2” or AGR2) AND (cancer or carcinoma or tumour or neoplasms). The references from selected articles were also examined by a hand search to find other relevant studies.

To be included in this meta-analysis, studies had to meet the following criteria: (1) The study evaluated the relationship between AGR2 expression and the prognosis of solid tumour patients, such as overall survival (OS) or disease-specific survival (DSS) or relapse-free survival (RFS) or disease-free survival (DFS) or progression-free survival (PFS) and clinicopathological features. (2) The study provided hazard ratios (HRs) with 95% confidence intervals (CIs) directly or these statistics could be calculated based on data presented. (3) A definite cut-off value to classify AGR2 expression as “positive” and “negative” or “high” and “low” was given. (4) Studies published in English or Chinese. (5) AGR2 expression was detected in tumour tissues or serum, rather than in cell lines. The exclusion criteria were as follows: (1) Reviews articles, letters, experimental studies, conference abstracts, case reports, duplicated publications or replicated samples. (2) Lacking sufficient data to estimate the HRs with 95% CIs. (3) Studies without OS or RFS or DFS or DSS or PFS for further quantification.

Two reviewers determined the eligibility of the screened studies independently. Discrepancies were solved by consensus after discussion.

---

Table 4. Meta-analysis of AGR2 overexpression and clinicopathological features of breast cancer.

| Stratification of breast cancer | NO. of study | References | Cases | Pooled OR (95% CI) | P value | Heterogeneity | I² (%) | p value |
|-------------------------------|--------------|------------|-------|------------------|--------|--------------|--------|---------|
| Tumor size (>5 cm/≤5 cm) | 2 | Wu et al.; Barraclough et al. | 464 | 1.35 (0.83–2.18) | 0.213 | 0 | 0.809 |
| Histological grade (III/I-II) | 5 | Fritzsche et al.; Innes et al.; Wu et al.; Barraclough et al.; Lacambra et al. | 1457 | 0.42 (0.19–0.93) | 0.032 | 85.3 | 0.000 |
| pT status (T3&T4/T1&T2) | 3 | Fritzsche et al.; Wu et al.; Lacambra et al. | 817 | 1.21 (0.76–1.92) | 0.431 | 0 | 0.632 |
| LVI(P/N) | 4 | Fritzsche et al.; Innes et al.; Wu et al.; Lacambra et al. | 1042 | 1.11 (0.84–1.46) | 0.469 | 25.8 | 0.257 |
| ER status (P/N) | 5 | Fritzsche et al.; Innes et al.; Wu et al.; Barraclough et al.; Lacambra et al. | 1468 | 4.08 (2.16–7.69) | 0.000 | 82.9 | 0.000 |
| HER-2 status (P/N) | 4 | Fritzsche et al.; Wu et al.; Barraclough et al.; Lacambra et al. | 1112 | 2.51 (0.84–7.51) | 0.099 | 91.5 | 0.000 |
| PgR status (P/N) | 4 | Innes et al.; Wu et al.; Barraclough et al.; Lacambra et al. | 1110 | 2.87 (2.17–3.80) | 0.000 | 0 | 0.702 |

---

Figure 5. Sensitivity analysis of the meta-analysis. (a) Sensitivity analysis for the AGR2 overexpression with OS. (b) Sensitivity analysis for the AGR2 overexpression with TTP.
Data extraction and methodological quality assessment. Two authors independently extracted relevant information from each eligible study using a standardized data collection form. The following data were collected: types of cancer, name of first author, publication year, country, the number of patients, age median, detection methods, location of AGR2 expression in tumour or serum, follow-up duration, outcome endpoints, and cut-off value to determine AGR2 positivity. When the prognosis was presented only as Kaplan-Meier curves in some studies, the Engauge Digitizer V4.1 was then utilized to obtain the survival data, and Tierney’s method to calculate the HRs and 95% CIs. The methodological quality of included studies was assessed by Newcastle-Ottawa Scale (NOS). The NOS consists of three quality parameters: selection (0–4 points), comparability (0–2 points), and outcome assessment (0–3 points). Studies with an NOS scores ≥ 6 were considered to be high-quality. Two reviewers performed the quality assessments separately.

Statistical analysis. We applied the HRs with 95% CIs to evaluate the impact of AGR2 overexpression on outcomes of solid tumour patients in this meta-analysis. For analysing the association between AGR2 high expression and clinicopathological features, odds ratios (ORs) with 95% CIs were assessed. Begg’s funnel plot and Egger’s test determined the potential publication bias among selected studies. P values were two-sided and P < 0.05 was considered to be statistically significant. Sensitivity analysis was tested to examine the stability of the pooled results. Inter-study heterogeneity was quantified using Q-tests and I-squared test. In the absence of significant heterogeneity (P > 0.10 or I² < 50%), a fixed effects model was appropriately used to calculate the pooled effect, otherwise the random effects model was employed. All statistical analyses were performed with Stata Version 12.0 (Stata Corporation, College Station, TX, USA).

References
1. Aberger, F., Weidinger, G., Greulich, H. & Richter, K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev 72, 115–30 (1998).
2. Raykhl, I. et al. A molecular specificity code for the three mammalian KDEL receptors. J Cell Biol 179, 1193–204 (2007).
3. Park, S. W. et al. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci USA 106, 6950–5 (2009).
4. Zhao, F. et al. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2−/− mice. Dev Biol 338, 279–90 (2010).
5. Blychtova, V., Vojetsek, B. & Hrstka, R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett 304, 1–7 (2011).
6. Pohler, E. et al. The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics 3, 534–47 (2004).
7. Fletcher, G. C. et al. HAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene Ca4a and dystroglycan. Br J Cancer 88, 579–85 (2003).
8. Vanderlaag, K. E. et al. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res 12, R32 (2010).
9. Fritzsche, F. R. et al. Expression of AGR2 in non small cell lung cancer. Histol Histopathol 22, 703–8 (2007).
10. Park, K. et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 43, 91–100 (2011).
11. Zhang, J. S., Gong, A., Cheville, J. C., Smith, D. I. & Young, C. Y. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 43, 249–59 (2005).
12. Rienert, M. O. et al. Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma. Histol Histopathol 24, 1121–8 (2009).
13. Lee, S., Bang, S., Song, K. & Lee, I. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep 16, 747–54 (2006).
14. Barracough, D. L. et al. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol 175, 1848–1857 (2009).
15. Alavi, M. et al. High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer 15, 1 (2015).
16. Hrstka, R., Blychtova, V., Fabian, P. & Vojtesek, B. & Svoboda, M. AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients. Dis Markers 35, 207–212 (2013).
17. Kristiansen, G. et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205, 359–376 (2005).
18. Armes, J. E. et al. AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation. Pathology 45, 49–54 (2013).
19. Rienert, M.-O. et al. Loss of Anterior Gradient-2 expression is an independent prognostic factor in colorectal carcinomas. Eur J Cancer 50, 1722–1730 (2014).
20. Fritzsche, F. R. et al. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 12, 1728–1734 (2006).
21. Innes, H. E. et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 94, 1057–1065 (2006).
22. Zhang, Y. et al. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 10, 293–300 (2007).
23. Wu, Z. S. et al. Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance. [Chinese]. Chinese Journal of Pathology 37, 109–113 (2008).
24. Hrstka, R. et al. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 29, 4838–4847 (2010).
25. Chung, K. et al. Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma. Cancer Biomark 10, 101–7 (2011).
26. Rudland, S. D. S. et al. Statistical Association of Basal Cell Keratins with Metastasis-Inducing Proteins in a Prognostically Unfavorable Group of Sporadic Breast Cancers. Am J Pathol 179, 1061–1072 (2011).
27. Chung, K. et al. AGR2 as a potential biomarker of human lung adenocarcinoma. Osaka city medical journal 58, 13–24 (2012).
28. Darb-Esfahani, S. et al. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma. Virchows Archiv 461, 109–116 (2012).
29. Valladas-Ayeres, M. et al. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int J Mol Sci 13, 4367–4387 (2012).
30. Hrstka, R. et al. AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway. Mol Oncol (2015).
31. Lacambra, M. D. et al. Anterior Gradient 2 is a Poor Outcome Indicator in Luminal Breast Cancer. Ann Surg Oncol 22, 3489–3496 (2015).
32. Zhang, J. et al. AGR2 is associated with gastric cancer progression and poor survival. Oncol Lett 11, 2075–2083 (2016).
33. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms (2017).
34. Shih, L. J. et al. Characterization of the agr2 gene, a homologue of X. laevis anterior gradient 2, from the zebrafish, Danio rerio. Gene Expr Patterns 7, 452–60 (2007).
35. Higa, A. et al. Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem 286, 48485–68 (2011).
36. Chevet, E. et al. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene 32, 2499–2509 (2012).
37. Arumugam, T. et al. New Blocking Antibodies against Novel AGR2-C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice. Mol Cancer Ther 14, 941–51 (2015).
38. Wang, Z., Hao, Y. & Lowe, A. W. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 68, 492–7 (2008).
39. Liu, D., Rudland, P. S., Sibson, D. R., Platt-Higgins, A. & Barraclough, R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 65, 3796–805 (2005).
40. Gupta, A., Wodzianik, D., Tun, M., Bouley, D. M. & Lowe, A. W. Loss of anterior gradient 2 (Agr2) expression results in hyperplasia and defective lineage maturation in the murine stomach. J Biol Chem 288, 4321–33 (2013).
41. Aberger, F., Weidinger, G., Gruz, H. & Richter, K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mechanisms of development 72, 115–130 (1998).
42. Kuang, W. W., Thompson, D. A., Hoch, R. V. & Weigel, R. J. Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic acids research 26, 1116–1123 (1998).
43. Vanderlaag, K. E. et al. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast cancer research: BCR 12, R32 (2010).
44. Ondrouskova, E. et al. AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. Exp Mol Pathol 102, 280–283 (2017).
45. Ramachandran, V., Arumugam, T., Wang, H. & Logdson, C. D. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 68, 7811–8 (2008).
46. Bu, H. et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 71, 575–87 (2011).
47. Edgell, T. A. et al. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) 118, 717–25 (2010).
48. Molter, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med 6, e1000097 (2009).
49. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007).
50. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Bmj 327, 557–60 (2003).

Acknowledgements
This work is supported by the National Natural Science Foundation of China (81402875 and 81576822), the Frontier Exploration Program of Huazhong University of Science and Technology (2015TS153), the Natural Science Foundation Program of Hubei Province (2015CFA049), the Research Fund of Public Welfare in Health Industry of the Health Ministry of China (201402015), and the Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST.

Author Contributions
S.B.T., K.X.T. and J.H. contributed to the design of the study and manuscript writing. S.B.T., K.X.T., K.L.C., J.B.G., X.L.D. and Z.B.L. contributed to the financial support and revision of the manuscript. All of the authors take responsibility for the integrity and accuracy of the study.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.